PubMed Health⌕ Search

PubMed · 9125020

Node-positive duodenal carcinoma is curable.

Abstract

OBJECTIVES: To document our experience with duodenal carcinoma during the past 15 years to ascertain optimal treatment. DESIGN: A retrospective case series. SETTING: A tertiary care referral center. PATIENTS: A consecutive sample of 24 patients, 17 men and 7 women, with duodenal carcinoma was evaluated during the 15 years ending in December 1992. Ages ranged from 44 to 81 years. All patients were available for follow-up for a minimum of 20 months. INTERVENTIONS: Therapy included 15 radical pancreaticoduodenectomies (Whipple procedures), 7 bypass operations, and 2 segmental resections. MAIN OUTCOME MEASURES: Tumor staging and survival. RESULTS: Segmental resections were performed in 2 patients, bypass operations in 7, and Whipple procedures in 15. One patient in each of the bypass and Whipple groups died postoperatively. All other patients who underwent bypass and segmental resection died of cancer. Of 14 patients surviving a Whipple procedure, 9 continue to survive with an average follow-up of 77 months. Four of these patients had lymph nodes involved with cancer and have survived for longer than 5 years. CONCLUSIONS: Adenocarcinoma of the duodenum gives rise to nonspecific gastrointestinal tract symptoms, and diagnosis is often delayed. Despite this delay, the Whipple procedure may still be curative for patients with positive lymph nodes, a fact poorly appreciated in the surgical literature. The role of segmental resection for distal duodenal tumors is unclear.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Pickleman, M Koelsch, G Chejfec. 1997. Node-positive duodenal carcinoma is curable.. https://doi.org/10.1001/archsurg.1997.01430270027004

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

The case for routine use of adjuvant therapy in pancreatic cancer.

Pancreatic cancer is a devastating disease with a poor prognosis for most patients. Surgical resection remains the cornerstone of treatment, providing the only realistic hope of long-term survival. Even with optimal surgical management, 5-year survival averages 15% to 20% for resectable disease. Progress is being made, however. Currently, the benefits of postoperative therapy for resected pancreatic ductal adenocarcinoma appear clear, and recommendations for such therapy appear to us to be well justified. Additional benefit to patients awaits the development of new agents, molecular targeted drugs, and novel approaches such as immunotherapy.

Adenocarcinoma↗

Proposal for a new definition of true cardia carcinoma.

BACKGROUND AND OBJECTIVES: It remains controversial whether cardia carcinoma should be categorized and treated as esophageal cancer or gastric cancer. The purpose of this study was to develop a reasonable definition of cardia carcinoma. METHODS: Patients with Siewert type II carcinomas were divided into two subgroups: 25 patients with a tumor center within 1 cm of the esophagogastric junction (EGJ) (type IIA) and 22 patients with tumor center 1-2 cm aboral of the EGJ (type IIB). Patients with subcardia carcinomas, 40 with invasion to the EGJ (type III) and 110 without (type IIIe-), were used as controls. RESULTS: The patients with type IIB carcinomas showed no different characteristics from those with type III or type IIIe- carcinomas, except for the stage of the disease. On the other hand, those with type IIA carcinomas were associated with a higher male/female ratio, higher incidences of elevated appearance, differentiated histology, and mediastinal node metastasis, and a significantly lower survival rate as compared with patients with subcardia carcinomas. Multivariate survival analysis revealed that type IIA is a significant prognostic determinant, but that type IIB is not. CONCLUSION: Type IIA carcinomas should be treated as true cardia carcinoma; type IIB as subcardia carcinoma. Our results should be confirmed by a prospective study.

Adenocarcinoma↗

Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer.

BACKGROUND: The prognosis of patients with liver metastasis from gastric cancer (LMGC) is dismal. The purpose of this study was to review our recent outcomes of hepatectomy for LMGC and to determine the suitable candidates for surgery. STUDY DESIGN: The outcomes of 37 patients with LMGC who underwent hepatectomy between 1990 and 2005 were assessed. No extrahepatic distant metastasis and feasibility of macroscopic curative resection were requisite indications for surgery. The prognostic values of clinicopathological factors were assessed by univariate and multivariate analyses. RESULTS: There was no in-hospital mortality. The median survival time and overall 5-year survival rate after hepatectomy of the patients with LMGC were 31 months and 11%, respectively. Intrahepatic recurrence following hepatectomy was found in 23 patients (62%). Variables independently associated with poor survival were bilobar metastasis (P = 0.002, CI = 1.9-16.3) and a maximum tumor diameter of >or= 4 cm (P = 0.006, CI = 1.4-7.7). The depth of the primary tumor and the timing of metastasis were not associated with survival. CONCLUSIONS: Surgical resection for LMGC may be indicated in patients with unilobar metastasis and/or tumors less than 4 cm in diameter. Synchronous metastasis is not a contraindication for hepatectomy.

Adenocarcinoma↗